Head-To-Head Comparison: Mateon Therapeutics (OTCMKTS:MATN) vs. iBio (NYSE:IBIO)

iBio (NYSE:IBIO) and Mateon Therapeutics (OTCMKTS:MATN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Valuation & Earnings

This table compares iBio and Mateon Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$300,000.00	282.11	-$24.91 million	($1.00)	-2.45
Mateon Therapeutics	N/A	N/A	-$6.64 million	($0.02)	-2.33

Mateon Therapeutics has lower revenue, but higher earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares iBio and Mateon Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-73.15%	-45.51%
Mateon Therapeutics	N/A	-64.66%	-42.92%

Risk and Volatility

iBio has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Insider and Institutional Ownership

7.9% of iBio shares are held by institutional investors. Comparatively, 0.1% of Mateon Therapeutics shares are held by institutional investors. 2.8% of iBio shares are held by company insiders. Comparatively, 39.2% of Mateon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for iBio and Mateon Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	0	0	3	0	3.00
Mateon Therapeutics	0	0	0	0	0.00

iBio presently has a consensus target price of $4.00, indicating a potential upside of 63.27%. Given iBio’s stronger consensus rating and higher probable upside, equities analysts plainly believe iBio is more favorable than Mateon Therapeutics.

Summary

Mateon Therapeutics beats iBio on 7 of the 12 factors compared between the two stocks.

About iBio

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

About Mateon Therapeutics

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.